Key Points
- CEO Michael Mahoney sold 160,901 shares on Feb. 2 at an average of $93.49 for about $15.04 million, reducing his stake by 10.23% to 1,411,735 shares; the sale was disclosed in an SEC filing.
- Boston Scientific trades near $91.56 (12‑month range $85.98–$109.50, 50‑day SMA $94.89, 200‑day SMA $99.29) and carries an analyst consensus of "Moderate Buy" with an average target of $123.26.
Boston Scientific Corporation (NYSE:BSX - Get Free Report) CEO Michael Mahoney sold 160,901 shares of the firm's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Boston Scientific Trading Down 0.3%
NYSE BSX opened at $91.56 on Wednesday. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The stock has a 50-day simple moving average of $94.89 and a 200 day simple moving average of $99.29. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $135.73 billion, a PE ratio of 48.96, a P/E/G ratio of 1.63 and a beta of 0.67.
Wall Street Analysts Forecast Growth
BSX has been the topic of a number of analyst reports. UBS Group reiterated a "buy" rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an "overweight" rating in a research report on Thursday, October 23rd. Weiss Ratings reissued a "buy (b-)" rating on shares of Boston Scientific in a report on Wednesday, January 21st. Evercore ISI set a $112.00 price objective on Boston Scientific in a research note on Monday, January 5th. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $132.00 to $131.00 and set a "buy" rating on the stock in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $123.26.
Read Our Latest Research Report on BSX
Institutional Trading of Boston Scientific
Institutional investors have recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its position in Boston Scientific by 8.1% during the 2nd quarter. Knights of Columbus Asset Advisors LLC now owns 68,862 shares of the medical equipment provider's stock worth $7,396,000 after acquiring an additional 5,188 shares during the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Boston Scientific by 1.9% during the 2nd quarter. Valeo Financial Advisors LLC now owns 22,038 shares of the medical equipment provider's stock worth $2,367,000 after acquiring an additional 417 shares in the last quarter. Headland Capital LLC raised its holdings in shares of Boston Scientific by 1.6% in the second quarter. Headland Capital LLC now owns 89,704 shares of the medical equipment provider's stock valued at $9,635,000 after purchasing an additional 1,441 shares during the last quarter. Finally, Valley National Advisers Inc. raised its holdings in shares of Boston Scientific by 26.1% in the second quarter. Valley National Advisers Inc. now owns 1,257 shares of the medical equipment provider's stock valued at $134,000 after purchasing an additional 260 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.
Boston Scientific Company Profile
(
Get Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
